News

AmpliTech Group Unit Rights Offering – Last Chance to Participate

AmpliTech Group Unit Rights Offering – Last Chance to Participate

AmpliTech Group's Unit Rights Offering Deadline Approaches

As the deadline approaches for AmpliTech Group, Inc. (NASDAQ: AMPG, AMPGW) regarding its unit rights offering, it is crucial for all eligible stakeholders to be aware of the remaining opportunity. The company reminds all those entitled to these unit rights that they must be exercised by 5:00 PM Eastern Time on December 10, 2025. This offering is a significant event for the company and its shareholders.

Understanding the Unit Rights Offering

AmpliTech's unit rights offering allows holders to purchase units at a rate of $4 per unit, with each unit bundled as follows: one common share and two purchase rights (Series A and Series B Rights) for additional common shares. Such a structure not only enhances shareholder engagement but also promotes broader participation in the company’s future endeavors.

Participation Privileges for Investors

For those who fully exercise their unit rights, there is an exciting oversubscription privilege that allows them to acquire additional units not purchased by other rights holders. This is subject to a pro-rata allocation and the availability of additional units. Hence, it is an excellent incentive for shareholders looking to increase their stake in AmpliTech Group.

Strategic Use of Proceeds

The raised funds from the unit rights offering are earmarked for several strategic initiatives. AmpliTech aims to bolster domestic manufacturing and operations, ramp up research and development projects, and foster product commercialization to ensure innovation remains at the forefront of their offerings. Additionally, the funds will be invested in enhancing supply chain resilience, pursuing pivotal strategic partnerships, and fueling overall corporate growth initiatives. This strategic plan illustrates AmpliTech's commitment to not only remain competitive but to lead in the rapidly evolving tech space.

Key Dates for the Offering

Shareholders should take note of the critical timelines surrounding the offering:

  • Rights Subscription Deadline: All subscriptions must be delivered before the expiry on December 10, 2025.
  • Subscription Prices: The exercise price for Series A Rights is set at $5 per share, while Series B Rights will be $6 each.
  • For those interested in Series A, the deadline for exercising these rights falls on July 18, 2026, and similarly for Series B, it extends until November 20, 2026.

Contacting AmpliTech Group

Stakeholders seeking further information are encouraged to reach out directly to MacKenzie Partners, Inc., the information agent for the offering, via email at AMPG@mackenziepartners.com. Alternatively, Moody Capital Solutions, Inc. is available to assist brokers, registered investment advisors, and institutions by contacting them at info@moodycapital.com.

Who Is AmpliTech Group, Inc.?

Founded with a vision to innovate, AmpliTech Group has positioned itself as a leader in the design and manufacturing of advanced radio frequency (RF) microwave components, specifically targeting 5G network solutions. Their comprehensive service areas span telecommunications, satellite communications, and even cutting-edge fields like quantum computing and space exploration. This breadth of expertise showcases AmpliTech's adaptability in meeting diverse customer needs across various high-tech industries.

Conclusion

In summary, this unit rights offering by AmpliTech Group serves as a pivotal occasion for current and potential shareholders. By investing in this opportunity, you are not only aligning with a forward-thinking company but also participating in its ambitious journey towards innovation and growth. Don't miss your chance to enhance your investment in AmpliTech Group.

Frequently Asked Questions

What is the deadline to participate in the unit rights offering?

The final deadline for participating in the unit rights offering is December 10, 2025, at 5:00 PM Eastern Time.

What do I receive if I participate in this offering?

Each unit purchased will consist of one common share along with rights to purchase additional shares at specified prices.

How will the proceeds from the offering be used?

AmpliTech plans to use proceeds to expand manufacturing, enhance product development, and support corporate growth initiatives.

Where can I find more information about the offering?

Shareholders can contact MacKenzie Partners, Inc. at AMPG@mackenziepartners.com for more details on the offering.

What types of rights are included in the unit offering?

The offering includes Series A and Series B Rights, each providing different prices for acquiring additional common shares.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 5

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

Black Diamond Group Achieves Key Milestones in Q3 2024

Updated Category News Views 251

Black Diamond Group Reports Strong Q3 2024 Performance Black Diamond Group Limited, recognized for its space rental and workforce accommodation solutions, recently reported its operating and financial results for the third quarter of 2024. The company has shown remarkable resilience with a strong foundation, enabling it to adapt to changing market dynamics and maintain...

Continue Reading
Potential Unicredit and Commerzbank Merger Promises Stakeholder Gains

Updated Category News Views 194

Unicredit and Commerzbank Merger: A Possible Game Changer The potential merger between Italy's Unicredit and Germany's Commerzbank has certainly caught the attention of the banking industry. In a recent interview with Handelsblatt, Unicredit's CEO, Andrea Orcel, shared his perspective, suggesting that this merger could bring significant advantages for all parties...

Continue Reading
Future Trends and Growth of Wearable Cardiac Devices in Healthcare

Updated Category News Views 100

Unlocking the Future of Wearable Cardiac Devices In the rapidly evolving landscape of healthcare technology, wearable cardiac devices have emerged as game-changers. These devices, which include smartwatches and ECG patches, are not just sophisticated gadgets; they represent the forefront of health monitoring. Predictions suggest that the global market for wearable cardiac...

Continue Reading
Pivotal Research Starts Coverage of Alphabet and Meta Stocks

Updated Category News Views 75

Pivotal Research Initiates Coverage of Alphabet and Meta Pivotal Research Group has recently begun coverage of Alphabet Inc. (NASDAQ: GOOGL), renowned for being the parent company of Google, assigning it a Buy rating. This rating comes from the assessment of Alphabet's strong competitive stance and promising growth trajectory in cloud computing and artificial intelligence...

Continue Reading
Innovative Belt Design Enhances Comfort and Style for All

Updated Category News Views 130

Revolutionizing Belt Design for Enhanced Functionality Inventors are always looking for ways to improve everyday items, and the MAGNET BELT is a prime example of innovative thinking. One inventor recognized the frustrations that come with traditional belt designs and sought a solution. "I envisioned a better method to secure the end portion of a belt to stop it from...

Continue Reading